Andreas G has saved the company !! If we take the dataset from Lithuania there are NO CARDIAC DEATHS OR IMBALANCES IN SAFETY/MORTALITY !! Clearly the FDA will understand that because the patients outside of Lithuania had underlying baseline conditions at a different rate that a subgroup analysis is acceptable. We expect accelerated approval with a labeled indication "Parsabiv for use in Lithuania where it's better than Sensipar"
